Compare Baxter International Inc (BAX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs TG Therapeutics Inc — how do they compare? Baxter International Inc trades at $26.95 (market cap $14.27B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Baxter International Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BAX | TGTX | |
|---|---|---|
Market Cap | $14.27B | $7.64B |
Sector | Health | Health |
52-Week High | $28.35 | $59.06 |
52-Week Low | $15.80 | $26.94 |
Enterprise Value | $21.79B | $7.84B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
